Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.
Frequently asked questions
What sector does Oncoinvent ASA (ONCIN) operate in?
Oncoinvent ASA belongs to the Other sector and operates in the Biotechnology industry.
What is Oncoinvent ASA (ONCIN) current stock price?
As of the latest data, Oncoinvent ASA stock price is NOK 90.00, with a previous close of NOK 88.00. Oncoinvent ASA gained NOK 2.00 in the last trading session, representing a 2.27% increase.
What is Oncoinvent ASA (ONCIN) current market capitalization?
Oncoinvent ASA market cap is approximately 403.06 million.
What is Oncoinvent ASA (ONCIN) Earnings Per Share (EPS)?
The trailing EPS is -NOK 125.00, and the forward EPS is -NOK 26.14.
Does Oncoinvent ASA (ONCIN) pay dividends?
No. Oncoinvent ASA does not pay a dividend.
When is Oncoinvent ASA (ONCIN) next earnings report?
Oncoinvent ASA is expected to release its next earnings report on June 30, 2026.
What is Oncoinvent ASA (ONCIN) beta (volatility) score?
Oncoinvent ASA has a beta of 3.747, indicating very high volatility compared to the market.